Tags

Type your tag names separated by a space and hit enter

Recombinant luteinizing hormone supplementation to recombinant follicle-stimulating hormone induced ovarian hyperstimulation in the GnRH-antagonist multiple-dose protocol.
Hum Reprod 2005; 20(5):1200-6HR

Abstract

BACKGROUND

Suppression of endogenous LH production by mid-follicular phase GnRH-antagonist administration in controlled ovarian hyperstimulation protocol using recombinant (rec) FSH preparations void of LH activity may potentially affect ovarian response and the outcome of IVF treatment. The present study prospectively assessed the effect of using a combination of recFSH and recLH on ovarian stimulation parameters and treatment outcome in a fixed GnRH-antagonist multiple dose protocol.

METHODS

127 infertile patients with an indication for IVF or ICSI were recruited and randomized (using sealed envelopes) to receive a starting dose of either 150 IU recFSH (follitropin alpha) or 150 IU recFSH plus 75 IU recLH (lutropin alpha) for ovarian hyperstimulation. GnRH-antagonist (Cetrorelix) 0.25 mg was administered daily from stimulation day 6 onwards up to and including the day of the administration of recombinant HCG (chorion gonadotropin alpha). Gonadotropin dose adjustments were allowed from stimulation day 6 onwards, HCG was administered as soon as three follicles > or =18 mm were present. The primary outcome parameter was treatment duration until administration of HCG.

RESULTS

Exogenous LH did not shorten the time necessary to reach ovulation induction criteria. Serum estradiol (E(2)) and LH levels were significantly higher on the day of HCG administration in the recLH-supplemented group (1924.7 +/- 1256.4 vs 1488.3 +/- 824.0 pg/ml, P < 0.03), and 2.1 +/- 1.4 vs 1.4 +/- 1.5 IU/l, P < 0.01, respectively).

CONCLUSIONS

Except for higher E(2) and LH levels on the day of HCG administration, no positive trend in favour of additional LH was found as defined by treatment outcome parameters.

Authors+Show Affiliations

University Clinic of Schleswig Holstein, Campus Luebeck, Germany. georg.griesinger@frauenklinik.uni-luebeck.deNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

15665010

Citation

Griesinger, G, et al. "Recombinant Luteinizing Hormone Supplementation to Recombinant Follicle-stimulating Hormone Induced Ovarian Hyperstimulation in the GnRH-antagonist Multiple-dose Protocol." Human Reproduction (Oxford, England), vol. 20, no. 5, 2005, pp. 1200-6.
Griesinger G, Schultze-Mosgau A, Dafopoulos K, et al. Recombinant luteinizing hormone supplementation to recombinant follicle-stimulating hormone induced ovarian hyperstimulation in the GnRH-antagonist multiple-dose protocol. Hum Reprod. 2005;20(5):1200-6.
Griesinger, G., Schultze-Mosgau, A., Dafopoulos, K., Schroeder, A., Schroer, A., von Otte, S., ... Felberbaum, R. (2005). Recombinant luteinizing hormone supplementation to recombinant follicle-stimulating hormone induced ovarian hyperstimulation in the GnRH-antagonist multiple-dose protocol. Human Reproduction (Oxford, England), 20(5), pp. 1200-6.
Griesinger G, et al. Recombinant Luteinizing Hormone Supplementation to Recombinant Follicle-stimulating Hormone Induced Ovarian Hyperstimulation in the GnRH-antagonist Multiple-dose Protocol. Hum Reprod. 2005;20(5):1200-6. PubMed PMID: 15665010.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Recombinant luteinizing hormone supplementation to recombinant follicle-stimulating hormone induced ovarian hyperstimulation in the GnRH-antagonist multiple-dose protocol. AU - Griesinger,G, AU - Schultze-Mosgau,A, AU - Dafopoulos,K, AU - Schroeder,A, AU - Schroer,A, AU - von Otte,S, AU - Hornung,D, AU - Diedrich,K, AU - Felberbaum,R, Y1 - 2005/01/21/ PY - 2005/1/25/pubmed PY - 2005/9/1/medline PY - 2005/1/25/entrez SP - 1200 EP - 6 JF - Human reproduction (Oxford, England) JO - Hum. Reprod. VL - 20 IS - 5 N2 - BACKGROUND: Suppression of endogenous LH production by mid-follicular phase GnRH-antagonist administration in controlled ovarian hyperstimulation protocol using recombinant (rec) FSH preparations void of LH activity may potentially affect ovarian response and the outcome of IVF treatment. The present study prospectively assessed the effect of using a combination of recFSH and recLH on ovarian stimulation parameters and treatment outcome in a fixed GnRH-antagonist multiple dose protocol. METHODS: 127 infertile patients with an indication for IVF or ICSI were recruited and randomized (using sealed envelopes) to receive a starting dose of either 150 IU recFSH (follitropin alpha) or 150 IU recFSH plus 75 IU recLH (lutropin alpha) for ovarian hyperstimulation. GnRH-antagonist (Cetrorelix) 0.25 mg was administered daily from stimulation day 6 onwards up to and including the day of the administration of recombinant HCG (chorion gonadotropin alpha). Gonadotropin dose adjustments were allowed from stimulation day 6 onwards, HCG was administered as soon as three follicles > or =18 mm were present. The primary outcome parameter was treatment duration until administration of HCG. RESULTS: Exogenous LH did not shorten the time necessary to reach ovulation induction criteria. Serum estradiol (E(2)) and LH levels were significantly higher on the day of HCG administration in the recLH-supplemented group (1924.7 +/- 1256.4 vs 1488.3 +/- 824.0 pg/ml, P < 0.03), and 2.1 +/- 1.4 vs 1.4 +/- 1.5 IU/l, P < 0.01, respectively). CONCLUSIONS: Except for higher E(2) and LH levels on the day of HCG administration, no positive trend in favour of additional LH was found as defined by treatment outcome parameters. SN - 0268-1161 UR - https://www.unboundmedicine.com/medline/citation/15665010/Recombinant_luteinizing_hormone_supplementation_to_recombinant_follicle_stimulating_hormone_induced_ovarian_hyperstimulation_in_the_GnRH_antagonist_multiple_dose_protocol_ L2 - https://academic.oup.com/humrep/article-lookup/doi/10.1093/humrep/deh741 DB - PRIME DP - Unbound Medicine ER -